There has been no significant breakthrough in the treatment of Systemic Lupus Erythematosus (SLE) for over 50 years. Treatment continues to rely on non-specific immunosuppressant drugs and glucocorticoids (GC, or ‘steroids’), and the impact on patients includes high mortality and poor quality of life. In this proposal, I will validate novel endpoints which will break the impasse in SLE drug development and develop tools for minimising GC use in SLE.
Targeting Autophagy As A Means Of Control Of Cytokine Production In SLE
Funder
National Health and Medical Research Council
Funding Amount
$616,518.00
Summary
Systemic lupus erythematosus (SLE, or lupus) is a common immune disease that causes organ damage and loss of life, chiefly affecting young women. There is no cure for SLE. We have discovered that a natural process called 'autophagy' could be a way to limit inflammation during SLE. In this project we will discover whether this could lead to a new way to treat this disease.
Rogue B Cell Clones In Patients With Autoimmune Disease
Funder
National Health and Medical Research Council
Funding Amount
$916,670.00
Summary
Our immune system protects us from disease by producing antibodies. However, 5% of Australians suffer from an autoimmune disease where they produce “auto” antibodies, which attack their own organs. This research will study the cells (termed B cells) responsible for making autoantibodies to determine how they differ from B cells that defend against disease. The goal is to develop therapies that eliminate autoantibody producing B cells from patients while preserving the immune system.
Exploring The Contribution Of Interferon-lambda To Autoimmune Disease
Funder
National Health and Medical Research Council
Funding Amount
$833,235.00
Summary
We have found that a novel protein, normally made in response to viral infections, is found in the blood of Lupus patients. This project will determine the cells that make this protein, what in Lupus blood makes these cells produce it and whether it plays a role in the severity of Lupus disease.
Optimising Osteoporosis Management In Young Adults
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Fragility fractures contribute to reduced quality of life in younger adults with chronic disease. However, tools for predicting these fractures and evidence for the best treatment to prevent them is lacking in this group. We aim to address these gaps in evidence through assessment of bone health in younger adults with two chronic diseases related to increased inflammation of either the bowel or joints, as they are the two leading conditions resulting in fragility fractures in younger adults.
The Effect Of Genetic Polymorphisms On The Development Of Systemic Lupus Erythematosus
Funder
National Health and Medical Research Council
Funding Amount
$50,741.00
Summary
Systemic lupus erythematosus is a debilitating disease that predominantly affects women of child-bearing age and may involve any organ. Genetics is one of the most well-recognised risk factors, and yet how genetics can cause lupus is unclear. This study involves examining the entire genetic sequence of individual patients to identify the mutations that cause the immune system to be dysregulated leading to disease.
Targeting Cytokine Signalling In Systemic Lupus Erythematosus
Funder
National Health and Medical Research Council
Funding Amount
$917,626.00
Summary
Systemic lupus erythematosus is a disease where the immune system attacks normally healthy tissues. The spontaneous overproduction of signalling molecules called interferons in lupus plays an important role in the severity of the disease. We have found that two proteins, named Bcl6 and PLZF, are important in controlling the interferon response in lupus patients. We propose that identifying how these proteins act to control interferon will aid in developing new treatments for lupus.
Interleukin 38: Uncoupling Innate Inflammation From Interferons In Lupus
Funder
National Health and Medical Research Council
Funding Amount
$1,048,669.00
Summary
Systemic lupus erythematosus (SLE) is an incurable autoimmune disease that affects 5 million patients worldwide, mostly young women. Grave multi-organ inflammation and substantial loss of life expectancy render SLE a critical unmet medical need. We found that the immune system protein interleukin 38 disables several signalling pathways essential for SLE progress. We will explore regulation and function of this protein in cells from healthy people and SLE patients and in models of the disease.
An estimated 5 million patients worldwide suffer from the autoimmune disease and in Australia and New zealand, autoimmune diseases affect around 1 in 20 people.Our research will investigate patients samples and animal models to identify the pathogenesis of autoimmune disease and establish new monitor systems and better therapeutic treatments of autoimmune diseases.